Finasteride
Product Images NDC 68071-1648

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68071-1648). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 1648 9

Label for Finasteride 5 mg tablets by NuCare Pharmaceuticals, Inc. The label states a quantity of 90 tablets and includes NDC number 68071-1648-9. It mentions prescription use (Rx Only) and includes manufacturer details, lot number, expiration date, and barcode. Storage instructions specify controlled temperature between 68-77°F.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' showing mean change from baseline plus or minus one standard error over four years. Two lines compare Placebo and Finasteride groups, with Finasteride showing a greater decrease in symptom scores over time. Sample sizes for each group at baseline and yearly intervals are indicated below the x-axis.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph comparing the percent of patients undergoing surgery for BPH, including TURP, over 48 months between Finasteride and Placebo groups. The graph shows lower cumulative surgery rates in the Finasteride group. Accompanying tables list cumulative events and patients at risk per year for both groups throughout the study period.*

FDA Label Image

Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Finasteride Fig3)

A line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' displaying mean percent change from baseline with time points from baseline to year 4. Two data series compare placebo and Finasteride groups, showing prostate volume changes over four years. Numbers of subjects for each group at each time point are listed below the graph.*

FDA Label Image

Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Finasteride Fig4)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' showing percent with event on the y-axis and years from randomization on the x-axis. Four treatment groups are plotted: Placebo, Finasteride, Doxazosin, and Combination, each represented with distinct markers and lines showing their cumulative incidence over 5.5 years.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of finasteride showing its steroidal framework with various functional groups including a ketone and an amide linkage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.